Beranda › Kanker Ginjal › New York › New York City
Uji klinis Kanker Ginjal di New York City, NY
15 studi untuk Kanker Ginjal mencari peserta di lokasi sekitar New York City (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Menerima pesertaFase 1
- Research Site, New York
- Research Site, New York
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Menerima pesertaFase 1
- NEO-811 NYC Site, New York
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Menerima pesertaFase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Menerima pesertaFase 3
- Research Site, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Menerima pesertaStudi observasional
- NYU Langone Medical Center, New York
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Menerima pesertaFase 1/2
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Center (BAIC), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
- dan 1 lainnya
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Menerima pesertaFase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Menerima pesertaFase 1
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
A Study of a Side Effects and Resource Navigation Program for People With Cancer
Menerima peserta
- City College of New York (Data Collection AND Specimen Analysis), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Brodalumab in the Treatment of Immune-Related Adverse Events
Menerima pesertaFase 1
- Columbia University Irving Medical Center, New York
Kidney Cancer DNA Registry
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Memorial Sloan Kettering Cancer Center, New York
Decision Aid (DA) for Renal Patients
Menerima peserta
- NYU Langone Health, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Menerima pesertaFase 1/2
- NYU Langone Health, New York
Uji klinis Kanker Ginjal di kota lain
- Nashville, TN12 studi
- Boston, MA12 studi
- Houston, TX10 studi
- San Diego, CA9 studi
- Dallas, TX9 studi
- St. Louis, MO9 studi
- Washington, DC9 studi
- Seattle, WA8 studi
- Edison, NJ8 studi
- Miami, FL8 studi
- Los Angeles, CA7 studi
- Jacksonville, FL7 studi
Studi lain di New York City
- Kanker Payudara136 studi
- Kanker Paru Non-Sel Kecil121 studi
- Kanker (semua jenis)109 studi
- Kanker Prostat103 studi
- Kanker Metastatik93 studi
- Kanker Kolorektal78 studi
- Kanker Ovarium69 studi
- Kanker Paru60 studi
- Mieloma Multipel60 studi
- Kanker Pankreas60 studi
- Kanker Endometrium52 studi
- Leukemia Mieloid Akut51 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.